Agonist News and Research

RSS

Genetic differences influence asthma risk in Latinos

Native American ancestry is associated with a lower asthma risk, but African ancestry is associated with a higher risk, according to the largest-ever study of how genetic variation influences asthma risk in Latinos, in whom both African and Native American ancestry is common. The study, led by UC San Francisco researchers, was published online October 6, 2014 in the Journal of Allergy and Clinical Immunology.

7 Oct 2014

Targeted treatments may improve idiopathic PAH survival

Patients with idiopathic pulmonary arterial hypertension may live longer if they are given targeted treatments than if they receive conventional management, researchers suggest.

29 Sep 2014

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

Tissue-level model of human airway musculature could pave way for patient-specific asthma treatments

The majority of drugs used to treat asthma today are the same ones that were used 50 years ago. New drugs are urgently needed to treat this chronic respiratory disease, which causes nearly 25 million people in the United States alone to wheeze, cough, and find it difficult at best to take a deep breath.

24 Sep 2014

LABA-ICS combination therapy better than LABAs alone for COPD

Among older adults with chronic obstructive pulmonary disease (COPD), particularly those with asthma, newly prescribed long-acting beta-agonists (LABAs) and inhaled corticosteroid combination therapy, compared with newly prescribed LABAs alone, was associated with a lower risk of death or COPD hospitalization, according to a study in the September 17 issue of JAMA.

17 Sep 2014

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Combined treatment with a drug that mimics the action of a gut hormone and basal insulin is more effective at improving blood sugar control than other anti-diabetic treatments, with similar rates of hypoglycaemia (dangerously low blood sugar levels) and greater weight loss, a systematic review and meta-analysis published in The Lancet shows.

15 Sep 2014

Sex hormone that helps protect females from stroke may also reduce risk of autism, say scientists

The same sex hormone that helps protect females from stroke may also reduce their risk of autism, scientists say.

10 Sep 2014

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

Boehringer Ingelheim today presented new data from the company's Phase III trial program (UniTinA-asthma®) evaluating tiotropium in asthma, including the first study assessing the efficacy and safety of tiotropium in adolescent patients with symptomatic asthma.

9 Sep 2014

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Mirabegron (trade name: Betmiga) has been approved since December 2012 for the treatment of adults with overactive bladder.

3 Sep 2014

Study suggests that energy drinks can cause heart problems

Energy drinks can cause heart problems according to research presented at ESC Congress 2014 today by Professor Milou-Daniel Drici from France.

1 Sep 2014

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Acromegaly is a chronic, life-threatening disease triggered by a benign tumour of the pituitary gland causing excessive growth hormone release. Oversupply of growth hormone stimulates liver, fat and kidney cells to produce excess levels of Insulin-Like Growth Factor I (IGFI), which causes abnormal growth of the bones of the hands, face and feet and bodily organs.

26 Aug 2014

Boehringer Ingelheim announces FDA acceptance of NDA filing for tiotropium and olodaterol FDC

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Aug 2014

Rettsyndrome.Org awards $1.5M to advance translational research, support Neuro-Habilitation Program

The International Rett Syndrome Foundation now doing business as Rettsyndrome.org announces today that the Board of Trustees has awarded $1.5M to support 10 new grants to further translational research and launch of the neuro-habilitation therapeutic program, and fund clinical research.

19 Aug 2014

Umeclidinium/vilanterol outperforms monotherapies in COPD

A combination of umeclidinium and vilanterol is more effective than each drug as monotherapy for the treatment of chronic obstructive pulmonary disease, research indicates.

13 Aug 2014

Fluticasone furoate effective in moderate-to-severe asthma

Once daily fluticasone furoate, used at a dose of 100 µg or 200 µg, provides substantial improvements in lung function and asthma control for patients with uncontrolled moderate-to-severe asthma, phase III trial results show.

13 Aug 2014

Heart failure is major public health burden in many LMICs

Heart failure is a major public health burden in many low- and middle-income countries (LMICs), with substantial variation in the presentation, causes, management, and outcomes of heart failure across different LMICs, according to a study published in this week's PLOS Medicine.

From CSL Ltd 13 Aug 2014

Only 52% of women receive low-cost treatment to prevent babies death

A major international study of more than 303 000 births in 29 low-income and middle-income countries has found that only half (52%) of women who are eligible to receive a simple, effective, low-cost treatment to prevent death and disability in their newborn babies are getting it.

13 Aug 2014

Mucosal lymphoid cells key to S. pneumoniae defence

Type 3 innate lymphoid cells in the lung mucosa are activated early in the course of infection with Streptococcus pneumoniae and are a major source of interleukin-22 production, research reveals.

11 Aug 2014

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Alexza Pharmaceuticals, Inc. today announced that ADASUVE inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza.

8 Aug 2014

Agonist News and Research

Genetic differences influence asthma risk in Latinos

Targeted treatments may improve idiopathic PAH survival

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Tissue-level model of human airway musculature could pave way for patient-specific asthma treatments

LABA-ICS combination therapy better than LABAs alone for COPD

Gut hormone-drug combination therapy more effective at improving type 2 diabetes

Sex hormone that helps protect females from stroke may also reduce risk of autism, say scientists

New data from Boehringer's Phase III trial program evaluates efficacy of tiotropium in asthma patients

No added benefit determined from Mirabegron for mortality, morbidity and quality of life

Study suggests that energy drinks can cause heart problems

Acromegaly and antisense therapy: an interview with Mark Diamond, CEO Antisense Therapeutics

Boehringer Ingelheim announces FDA acceptance of NDA filing for tiotropium and olodaterol FDC

Rettsyndrome.Org awards $1.5M to advance translational research, support Neuro-Habilitation Program

Umeclidinium/vilanterol outperforms monotherapies in COPD

Fluticasone furoate effective in moderate-to-severe asthma

Heart failure is major public health burden in many LMICs

Only 52% of women receive low-cost treatment to prevent babies death

Mucosal lymphoid cells key to S. pneumoniae defence

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News